Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
$4.62M
Dr. David Young Ph.D., Pharm.D.
15.00
Hanover, MD
Nov 21, 2013
-0.27
$-5.25
3.59
4.82
0.00%
-0.41
0.00
0.70
0.00
4.82
-134.50%
-151.10%
Similar stocks (16)
Celcuity Inc.
CELC
Third Harmonic Bio, Inc.
THRD
Eliem Therapeutics, Inc.
ELYM
Inhibrx, Inc.
INBX
Fennec Pharmaceuticals Inc.
FENC
PMV Pharmaceuticals, Inc.
PMVP
Armata Pharmaceuticals, Inc.
ARMP
Anebulo Pharmaceuticals, Inc.
ANEB
Akari Therapeutics, Plc
AKTX
Acurx Pharmaceuticals, Inc.
ACXP
AN2 Therapeutics, Inc.
ANTX
SAB Biotherapeutics, Inc.
SABS
Inhibikase Therapeutics, Inc.
IKT
Fresh Tracks Therapeutics, Inc.
FRTX
Comera Life Sciences Holdings, Inc.
CMRA
Scopus BioPharma Inc.
SCPS
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (16)
Celcuity Inc.
CELC
Third Harmonic Bio, Inc.
THRD
Eliem Therapeutics, Inc.
ELYM
Inhibrx, Inc.
INBX
Fennec Pharmaceuticals Inc.
FENC
PMV Pharmaceuticals, Inc.
PMVP
Armata Pharmaceuticals, Inc.
ARMP
Anebulo Pharmaceuticals, Inc.
ANEB
Akari Therapeutics, Plc
AKTX
Acurx Pharmaceuticals, Inc.
ACXP
AN2 Therapeutics, Inc.
ANTX
SAB Biotherapeutics, Inc.
SABS
Inhibikase Therapeutics, Inc.
IKT
Fresh Tracks Therapeutics, Inc.
FRTX
Comera Life Sciences Holdings, Inc.
CMRA
Scopus BioPharma Inc.
SCPS
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%